1.	How often do you encounter patients with persistent reflux symptoms despite management therapy?
a) Rarely (less than 10%)
b) Occasionally (10–25%)
c) Frequently (25–50%)
d) Very often (>50%)

2.	What, in your opinion, is the most common reason for suboptimal response to PPI/ other management therapy?
a) Poor compliance or incorrect timing
b) Nocturnal or non-acid reflux
c) Functional heartburn or hypersensitivity
d) True PPI resistance

3.	Which subgroup of GERD patients do you find most challenging to manage?
a) Nocturnal Acid Breakthrough
b) Obese or post-bariatric patients
c) Patients on chronic NSAIDs
d) Functional dyspepsia overlap cases
4.	Have you prescribed Vonoprazan or any P-CAB in your practice?
a) Yes, regularly
b) Yes, occasionally
c) Tried in few selected cases
d) Not yet, but aware of it
5.	In which patient profiles would you consider next-generation acid suppression as first choice?
a) PPI non-responders
b) Severe or erosive GERD
c) High-risk or frequent relapsers
d) All of the above
6.	How many cases of H. pylori infection do you encounter, on average, per month in your clinical practice?
a)	Fewer than 5 cases
b)	5 - 15 cases
c)	16 - 30 cases
d)	More than 30 cases

7.	What is your current first-line therapy for H. pylori eradication?
a)	PPI + Amoxicillin + Clarithromycin
b)	PPI + Amoxicillin + Metronidazole
c)	PPI + Bismuth + Tetracycline + Metronidazole
d)	Sequential therapy: PPI + Amoxicillin for 7 days followed by PPI + Amoxicillin + Clarithromycin + Metronidazole for 7 days
e)	PPI + Amoxicillin + Levofloxacin
8.	In your clinical experience, how effective are conventional PPI-based triple therapy regimens in achieving H. pylori eradication?
a. >90% eradication consistently
b. 80–90% eradication
c. 70–80% eradication
d. <70% eradication / frequent failures

9.	What do you consider the primary benefits of Vonoprazan over traditional PPIs for H. pylori eradication? 
a.	Faster onset of acid suppression
b.	Stronger and more sustained acid suppression
c.	Reduced variability due to CYP2C19 polymorphisms
d.	Meal-independent dosing


10.	What are the challenges have you faced with PPI-based H. pylori treatment?
Ans.¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬____________________________________________________________ 
